Clinical Trial

Psilocybin rTMS for Treatment Resistant Depression

Study acronym: PSILOBSD
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with treatment-resistant major depressive disorder.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-11-09; most recent amendment 2025-11-20.
Status change: Not Yet Recruiting → Recruiting 2025-09-18
Trial Details
NCT Number NCT06132178
Lead Sponsor University of Texas at Austin
Conditions Treatment Resistant Depression, MDD, Major Depressive Disorder, Recurrent Depression, Depression
Enrollment 100 participants
Start Date 2025-01-10
Primary Completion 2029-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-26